Companies Dominating the Autism Diagnostics Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Curemark LLC
- Yamo Pharmaceuticals, LLC
- Merck & Co Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Services, Inc.
- Bristol-Myer Squibb
- Janssen Pharmaceuticals, Inc.
- Axial Therapeutics, Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Novartis AG announced collaboration with Sangamo to research gene therapies for the treatment of autism spectrum disease. The top two brands will partner to develop gene therapies and other brain problems for ASD treatments. The agreement between Novartis and Sangamo provided the Brisbane-based firm with a net worth of approximately USD 75 million to accomplish the milestones in its commercial development.
- Axial Therapeutics announced that the company received clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for their lead candidate named AB-2004, which is a gut targeted, molecular therapeutic being studied for the treatment of irritability associated with ASD.
